Imaging evaluation of response in NSCLC R. Efthymiadou. Minimal thoracic surgery-maximum efficacy. What new in 2018 K. Iliadis

Transcription

1 I N T Lung Cancer Seminar E R N A T I O N A L friday September 14, Registration opens LECTURE I Chairpersons: V. Iordanoglou, Ch. Marinou Smoking and lung cancer epidemiology D. Kyroussis LECTURE II Chairpersons: P. Mavroudis, J. Davlopoulos Imaging evaluation of response in NSCLC R. Efthymiadou LECTURE III Chairpersons: L. Zellos, K. Poulopoulos Minimal thoracic surgery-maximum efficacy. What new in 2018 K. Iliadis LECTURE IV Chairpersons: E. Samantas, E. Mirogiorgou Thromboembolic events in NSCLC. Is there a real threat? V. Barbounis LECTURE V Chairpersons: Ch. Bakogiannis, K. Tsigaridas Nanotechnology: the clinical benefit for patients with advanced NSCLC G. Lainakis Coffee break 10

2 friday September 14, WORKSHOP: CARCINOID LUNG TUMORS Chairpersons: D. Baltagiannis, M. Theochari, E. Res Surgery: state of the art: L. Zellos Targeted treatment: A. Koumarianou ROUND TABLE I: MESOTHELIOMA Chairpersons: A. Petounis, A. Mallios, F. Matsouka Surgery L. Toufektzian Chemotherapy and antiangiogenesis N. Pistamaltzian Immunotherapy D. Tryfonopoulos LECTURE VI Chairpersons: N. Kentepozidis, Ch. Panopoulos Could individualized sequencing of ALK-inhibitors lead to an optimal patient s outcome? V. Ramfidis ROUND TABLE II: MOLECULAR CHARACTERIZATION OF LUNG CANCER BEYOND ADENOCARCINOMA Chairpersons: S. Murray, N. Xiros, D. Thomaidou xtargeting genome alteration in squamous cell lung cancer G. Rigakos Targeting developmental pathways in small cell lung cancer K. Ploiarchopoulou Opening Ceremony Chairpersons: P. Kosmidis, K. Iliadis Welcome addresses Opening lecture O Πολιτισμός των Περιστεριώνων Πατέρας Μάρκος Φώσκολος Αρχειοφύλακας και βιβλιοθηκάριος της Καθολικής Αρχιεπισκοπής Τήνου Φωτογραφίες: Αριστείδης Κοντογεώργης Καθηγητής Πανεπιστημίου Δυτικής Αττικής Welcome Reception 11

3 I N T Lung Cancer Seminar E R N A T I O N A L Saturday September 15, LECTURE VII Chairpersons: G. Fountzilas, A. Laskarakis 1 st line chemotherapy for non oncogene anticted lung cancer. Is still an option? M. Tsiatas ROUND TABLE III: SECOND LINE TRATMENT IN NON-ONCOGENE ADDICTED LUNG CANCER Chairpersons: D. Pectasides, E. Mirogiorgou Chemotherapy combined with antiangiogenics. Which patients? G. Lypas Immunotherapy. Which patient J. Alafis Hyperproggressive disease. Which choice? N. Kentepozidis ROUND TABLE IV: FIRST LINE FOR ONCOGENE ADDICTED LUNG CANCER Chairpersons: E. Samantas, I. Alafis, V. Rapti Key factors that determine the selection of first line EGFR TKI C. Emmanouilidis Key factors that determine the selection of first line ALK inhibitors C. Andreadis Key factors that determine the selection of first line B-RAF inhibitors P. Kosmidis Is PFS a relevant and-point for first line TKI s C. Panopoulos Coffee Break 12

4 saturday September 15, ROUND TABLE V: RESISTANCE TO TKI S Chairpersons: A. Alexopoulos, H. Galani, M. Liontos Therapeutic strategies to overcome EGFR resistance M. Nikolaidou Therapeutic strategies to overcome ALK and ROS-1 resistance E. Galani Local treatment on oligometastatic disease. When? How? A. Laskarakis ROUND TABLE VI: NEXT GENERATION EGFR TKI Chairpersons: V. Georgoulias, E. Lianos, L. Florentin Frontline A. Grivas Later K. Tsigaridas LECTURE VIII Chairpersons: D. Bafaloukos, G. Nasioulas Next Generation ALK TKI. Is frontline better? F. Stavridi Light Lunch LECTURE IX Chairpersons: J. Varthalitis, G. Oikonomopoulos Immunotherapy in NSCLC. From monotherapy to combined immunotherapy and the role of new biomarkers H. Linardou 13

5 I N T Lung Cancer Seminar E R N A T I O N A L ROUND TABLE VII: IMMUNOTHERAPY IN EARLY STAGE NSCLC Chairpersons: P. Papakostas, Z. Saridaki, M. Tsiatas Adjuvant treatment S. Demiri Neoadjuvant treatment C. Pappa In combination with Radiation in stage III P. Skarlos DEBATE I: IMMUNOTHERAPY FIRST LINE IN NSCLC Chairpersons: P. Kosmidis, P. Oikonomopoulou Combined with chemotherapy I. Boukovinas Monotherapy Z. Saridaki Coffee Break LECTURE X Chairpersons: A. Psyrri, M. Theochari Maintenance immunotherapy in stage III NSCLC I. Athanasiadis DEBATE II: ELDERLY PATIENTS WITH EARLY STAGE NSCLC Chairpersons: L. Toufexian, G. Kolitsi, G. Koumakis Surgery N. Baltagiannis SBRT S. Kosmidi 14

6 sunday September 16, 2018 Sunday September 16, ROUND TABLE VIII: NEW MOLECULAR TARGETS OF INTEREST Chairpersons: G. Oikonomopoulos, C. Pappa, Th. Floros B-RAF M. Liontos MET RET J. Alafis HER-2 M. Lianos ROUND TABLE IX: COMBINED TREATMENT IN STAGE III NSCLC Chairpersons: K. Kyprianou, Ch. Bakogiannis, P. Skarlos When concurrent chemoradiotherapy is not the preferred choice A. Giannopoulou Surgical salvage of local recurrences following chemoradiotherapy. Indication and outcome K. Iliadis Radiation combined with targeted treatments. Is it possible and promising? G. Maravelis ROUND TABLE X: ASCO 2018 Chairpersons: N. Karvounis, H. Goniotaki, M. Katsikas Small cell lung cancer E. Mirogiorgou NSCLC: Chemotherapy M. Theochari NSCLC: Targeted therapy E. Res NSCLC: Immunotherapy D. Nasi CLOSING REMARKS 15